Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases

Duplaine, Alexandra; Beylot‐Barry, M.; Mansard, Sandrine; Arnault, Jean‐Philippe; Grob, Jean‐Jacques; Maillard, H.; Saïag, Philippe; Poulalhon, Nicolas; Cribier, B.; Mortier, Laurent; Battistella, Maxime; Jouary, Thomas

doi:10.1016/j.jaad.2021.05.024

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, there is a recent report of an association between a low-grade malignant variant of trichoblastoma and sonic hedgehog pathway mutations [ 21 ]. Vismodegib, an FDA-approved sonic hedgehog pathway inhibitor indicated for locally advanced or metastatic BCC, has exhibited promising results in the treatment of advanced TBC with better tolerability than sunitinib [ 17 , 20 , 22 ]. A recent phase II study with nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, also demonstrated promising results with an 80% one-year survival rate and 54.5% progression-free survival at six months in 11 patients with advanced TBC [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Trichoblastic Carcinoma in the Glabella Treated With Mohs Micrographic Surgery

Park,

Crasto,

Kubicki

et al. 2024

Cureus

View full text Add to dashboard Cite

Trichoblastic carcinoma (TBC) is a rare adnexal neoplasm of follicular germ cell differentiation with the potential for local invasion and metastasis. Histologic features of trichoblastic carcinoma have significant overlap with trichoblastoma and basal cell carcinoma (BCC), making diagnosis difficult in some cases. Treatment strategies are not well defined and include surgical excision for localized tumors and systemic therapies for metastatic disease. We present a case of trichoblastic carcinoma clinically resembling a benign cyst that was ultimately treated with Mohs micrographic surgery (MMS).

show abstract

Section: Discussionmentioning

confidence: 99%

Trichoblastic Carcinoma in the Glabella Treated With Mohs Micrographic Surgery

Park,

Crasto,

Kubicki

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat some types of non-small cell lung cancer and advanced pancreatic cancer ( Carter et al, 2022 ). Vorinostat ( Lin et al, 2021 ), dacomitinib ( Ji et al, 2021 ), vandetanib ( Carvalho et al, 2022 ), afatinib ( Wu et al, 2021 ), and vismodegib ( Duplaine et al, 2021 ) also have anticancer effects in malignancies. In the future, further experiments are required to confirm their therapeutic potential for the targeted therapy of HCC.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of m5C-Related lncRNAs in the prognosis and immune landscape of hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

5-Methyladenosine (m5C) is a type of epigenetic modification involved in the progression of various cancers. To investigate the role of m5C-related long non-coding RNAs (lncRNAs) in the prognosis and immune cell infiltration in hepatocellular carcinoma (HCC), we obtained patients’ clinical information and transcriptome data of HCC from the Cancer Genome Atlas (TCGA) database. We applied Pearson correlation analysis to construct an m5C-related lncRNA–messenger RNA (mRNA) co-expression network. Univariate Cox analysis, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analysis were employed to establish an m5C-related lncRNA prognostic risk model. We then verified the model using Kaplan–Meier analysis, principal component analysis, as well as univariate and multivariate Cox analyses. The expression of m5C-related lncRNAs was validated in HCC tissues and different cell lines. Combining the risk score and clinicopathological features, a nomogram was established for predicting the overall survival (OS) of HCC patients. Furthermore, gene set enrichment analysis (GSEA) revealed that some tumor-associated pathways were significantly enriched in the high-risk group. Immune cell infiltration analysis demonstrated that the levels of Treg cells, neutrophils, and M2 macrophages were higher in the high-risk group. In addition, patients with high tumor mutation burden (TMB) had worse OS than those with low TMB. We also assessed the immune checkpoint level and chemotherapeutic agent sensibility. Then in vitro experiments were performed to examine the biological function of MKLN1-AS in HCC cells and found that knockdown of MKLN1-AS suppressed the proliferation, migration, and invasion. In conclusion, m5C-related lncRNAs played a critical role in predicting the prognosis of patients with HCC and may serve as new therapeutic targets for HCC patients.

show abstract